Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James Xu

Showing results (41-50 of 44) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 44 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 23, 2019
Analysis of the Association Between Adverse Events and Outcome in Patients Receiving a Programmed Death Protein 1 or Programmed Death Ligand 1 AntibodyV Ellen Maher, Laura L Fernandes, Chana Weinstock, et al.
Nucleic Acids Research|March 24, 2017
CDK12 regulates alternative last exon mRNA splicing and promotes breast cancer cell invasionJerry F Tien, Alborz Mazloomian, S-W Grace Cheng, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 1, 2020
Regulatory Considerations for Contribution of Effect of Drugs Used in Combination Regimens: Renal Cell Cancer Case StudiesJamie R Brewer, Elaine Chang, Sundeep Agrawal, et al.
Archives of Toxicology|August 27, 2013
Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADMEPatricio Godoy, Nicola J Hewitt, Ute Albrecht, et al.
Pageof 5

Showing results (41-50 of 44) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 44 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 23, 2019
Analysis of the Association Between Adverse Events and Outcome in Patients Receiving a Programmed Death Protein 1 or Programmed Death Ligand 1 AntibodyV Ellen Maher, Laura L Fernandes, Chana Weinstock, et al.
Nucleic Acids Research|March 24, 2017
CDK12 regulates alternative last exon mRNA splicing and promotes breast cancer cell invasionJerry F Tien, Alborz Mazloomian, S-W Grace Cheng, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 1, 2020
Regulatory Considerations for Contribution of Effect of Drugs Used in Combination Regimens: Renal Cell Cancer Case StudiesJamie R Brewer, Elaine Chang, Sundeep Agrawal, et al.
Archives of Toxicology|August 27, 2013
Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADMEPatricio Godoy, Nicola J Hewitt, Ute Albrecht, et al.
Pageof 5